Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paclitaxel

FDA-approved product (injectable, injection), marketed as Abraxane, Paclitaxel, Taxol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Paclitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • HER2 Positive Breast Carcinoma
  • Kaposi's sarcoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Non-small cell lung carcinoma
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Undifferentiated carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paclitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paclitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

    NCT04974047 · start 2021-08-17

    Registered record
    Registry ID
    NCT04974047
    Conditions
    Resectable Esophageal Squamous Cell Carcinoma
    Interventions
    Tislelizumab; Paclitaxel; Cisplatin; 5-fluorouracil; Radiotherapy; Surgical resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-08-17
    Completion
    2024-10-25
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResectable Esophageal Squamous Cell Carcinoma
    InterventionTislelizumab; Paclitaxel; Cisplatin; 5-fluorouracil +2 more
    PhasePhase 2
    Registry statusCompleted

  • Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

    NCT04784715 · start 2021-04-26

    Registered record
    Registry ID
    NCT04784715
    Conditions
    Breast Cancer; HER2-positive; Metastatic
    Interventions
    Trastuzumab deruxtecan; Placebo; Taxane; Pertuzumab; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-04-26
    Completion
    2029-12-30
    Enrolment
    1,157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; HER2-positive; Metastatic
    InterventionTrastuzumab deruxtecan; Placebo; Taxane; Pertuzumab +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

    NCT05035147 · start 2021-03-25

    Registered record
    Registry ID
    NCT05035147
    Conditions
    Pancreatic Cancer
    Interventions
    albumin-bound paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2021-03-25
    Completion
    2026-12
    Enrolment
    934

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    Interventionalbumin-bound paclitaxel
    PhasePhase 4
    Registry statusRecruiting

  • Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

    NCT07115095 · start 2021-01-01

    Registered record
    Registry ID
    NCT07115095
    Conditions
    HER2-positive Breast Cancer
    Interventions
    TP Chemotherapy + Trastuzumab + Pertuzumab; TP Chemotherapy + Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2023-01-01
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer
    InterventionTP Chemotherapy + Trastuzumab + Pertuzumab; TP Chemotherapy + Trastuzumab
    PhaseNot applicable
    Registry statusCompleted

  • A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

    NCT04015778 · start 2019-08-08

    Registered record
    Registry ID
    NCT04015778
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Nivolumab; carboplatin; nab-paclitaxel; Radical resection for lung cancer; Radical radiation therapy; Chemotherapy (Cisplatin); Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-08-08
    Completion
    2026-08-30
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionNivolumab; carboplatin; nab-paclitaxel; Radical resection for lung cancer +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    NCT03839823 · start 2019-02-25

    Registered record
    Registry ID
    NCT03839823
    Conditions
    Breast Cancer
    Interventions
    Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2023-05-10
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib +2 more
    PhasePhase 2
    Registry statusCompleted

  • ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

    NCT04172259 · start 2019-01-10

    Registered record
    Registry ID
    NCT04172259
    Conditions
    Breast Cancer; Neoadjuvant Chemotherapy
    Interventions
    Doxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel; Epirubicin; Pertuzumab; Paclitaxel; Paclitaxel-albumin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-01-10
    Completion
    2026-09-30
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Neoadjuvant Chemotherapy
    InterventionDoxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

    NCT03632798 · start 2018-08-01

    Registered record
    Registry ID
    NCT03632798
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    ChemoID assay; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-08-01
    Completion
    2019-06-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    InterventionChemoID assay; Chemotherapy
    PhasePhase 3
    Registry statusWithdrawn

  • Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

    NCT02876302 · start 2018-01-24

    Registered record
    Registry ID
    NCT02876302
    Conditions
    Inflammatory Breast Cancer (IBC)
    Interventions
    Ruxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-24
    Completion
    2024-10-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Breast Cancer (IBC)
    InterventionRuxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    PhasePhase 2
    Registry statusCompleted

  • Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

    NCT03580395 · start 2017-06-01

    Registered record
    Registry ID
    NCT03580395
    Conditions
    Breast Cancer
    Interventions
    Apatinib; paclitaxel; cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2017-06-01
    Completion
    2022-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionApatinib; paclitaxel; cisplatin
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

    NCT02892123 · start 2016-09-30

    Registered record
    Registry ID
    NCT02892123
    Conditions
    HER2-expressing Cancers
    Interventions
    ZW25 (Zanidatamab); Paclitaxel; Capecitabine; Vinorelbine; Tucatinib; Tucatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-30
    Completion
    2024-10-31
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-expressing Cancers
    InterventionZW25 (Zanidatamab); Paclitaxel; Capecitabine; Vinorelbine +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

    NCT02670746 · start 2015-10-01

    Registered record
    Registry ID
    NCT02670746
    Conditions
    Pancreatic Neoplasms
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2015-10-01
    Completion
    2017-11-28
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Neoplasms
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

    NCT02367794 · start 2015-06-11

    Registered record
    Registry ID
    NCT02367794
    Conditions
    Squamous Non-Small Cell Lung Cancer
    Interventions
    Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody; Carboplatin; Nab-Paclitaxel; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06-11
    Completion
    2021-02-17
    Enrolment
    1,021

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Non-Small Cell Lung Cancer
    InterventionAtezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody; Carboplatin; Nab-Paclitaxel; Paclitaxel
    PhasePhase 3
    Registry statusCompleted

  • Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

    NCT02178436 · start 2014-10-31

    Registered record
    Registry ID
    NCT02178436
    Conditions
    Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer
    Interventions
    gemcitabine hydrochloride; Selinexor; Pharmacological Study; Laboratory Biomarker Analysis; Nab paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-10-31
    Completion
    2023-04-05
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer
    Interventiongemcitabine hydrochloride; Selinexor; Pharmacological Study; Laboratory Biomarker Analysis +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

    NCT02083679 · start 2014-07

    Registered record
    Registry ID
    NCT02083679
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine; Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed; Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel; Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-07
    Completion
    2015-08
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionPart 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine; Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed; Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel; Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
    PhasePhase 1
    Registry statusTerminated